Search
A new finding provides insight into how breast cancer develops resistance to aromatase inhibitors.
Lung resection after initial nonoperative treatment for non-small cell lung cancer (NSCLC) was safe and led to significantly improved survival in select patients previously treated with nonoperative therapies, according to a study by Memorial Sloan Kettering Cancer Center (MSK) investigators.
Memorial Sloan Kettering Cancer Center (MSK) is committed not only to providing exceptional cancer care but also to ensuring access to care for everyone who needs it. Unfortunately, some patients — often those whose insurance plan offers a very narrow provider network or those who are underinsured — have trouble shouldering the significant financial burden that can come with a cancer diagnosis. MSK has a special team in place to make sure these patients can still get the care they deserve.
El Memorial Sloan Kettering Cancer Center (MSK) se compromete no solo a brindar una atención excepcional para combatir el cáncer, sino también, a asegurar el acceso a la atención para todo aquel que lo necesite. Desafortunadamente, algunos pacientes (generalmente aquellos cuyo seguro ofrece una red de servicios muy reducida o aquellos que no están asegurados) se encuentran en problemas para afrontar la gran carga financiera que conlleva un diagnóstico de cáncer. MSK cuenta con un equipo especial que se asegura de que estos pacientes puedan recibir la atención que se merecen.
A targeted approach being developed to treat certain cancers may also be effective for Alzheimer’s disease.
Results from a large phase III clinical trial unveiled at this year’s ASCO meeting identify an effective targeted therapy for a subset of people with pancreatic cancer.
Patients with high-grade epithelial ovarian cancer with recurrence after neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) had similar outcomes following secondary cytoreduction surgery (SCS) compared to patients with recurrence after primary debulking surgery (PDS), according to a retrospective study by Memorial Sloan Kettering Cancer Center (MSK) Team Ovary.
An MSK study explains how the drug selinexor, which was recently approved to treat multiple myeloma and is being tested in many other tumor types, stops cancer.
More than 20 years ago, this SKI scientist laid the groundwork for a field that is now transforming medicine.
Learn how MSK helps people facing cancer in every way they need, and understands the importance of speaking to patients in the language that provides them peace of mind.